Lucas Sigman, director general of Chemo, a leader in the research, development and manufacture of finished dosage forms and the active pharmaceutical ingredient arm of Insud Pharma, highlights the 40 years of expertise of the company in manufacturing for generic players globally and discusses how the recent EUR 30 million investment in the two manufacturing sites producing injectables makes the company stand out as the partner of choice for their customers.
It is an exciting time for the group, with the rebranding and structural changes dividing the group into Chemo, Exeltis and mAbxience. What is the rational for such changes at this moment in time?
"Spain is a natural place for us to be"
